VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vir Biotechnology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$10.21+0.25 (+2.51%)
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
Vir Biotechnology, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| License and collaboration revenue | $63.13M | $61.37M | $37.38M | – | – | – | – | – | – | 92.1% | +2.9% |
| Other revenue | $3.39M | $2.34M | $2.11M | – | – | – | – | – | – | 4.9% | +44.7% |
| Grant revenue | $2.04M | $10.49M | $46.69M | $35.33M | $8.35M | – | – | – | – | 3.0% | -80.6% |
| Profit-sharing amount previously constrained, released | $0 | $0 | $35.73M | $0 | $0 | – | – | – | – | 0.0% | – |
| Profit-sharing amount constrained | $0 | -$699.00K | $0 | -$369.68M | $0 | – | – | – | – | 0.0% | -100.0% |
| Profit-sharing amount | -$1.14M | $9.08M | $1.54M | $1.88B | $917.19M | – | – | – | – | -1.7% | -112.5% |
| Other revenue | – | $55.33M | $2.23M | $52.71M | $169.87M | $44.50M | $711.00K | $868.00K | $149.00K | – | – |
| License | – | – | – | $22.29M | $0 | $22.75M | $0 | – | – | – | – |
| Collaboration revenue | – | $8.38M | $37.27M | $1.51B | $917.19M | $0 | $0 | – | – | – | – |
| License Revenue | – | $0 | $0 | $22.29M | $0 | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Vir Biotechnology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.